28Bio
Private Company
Funding information not available
Overview
28Bio is a private, preclinical-stage biotech leveraging its proprietary Nexon™ platform to create engineered human brain and peripheral nervous system organoids for neurotoxicity and efficacy testing. The company's technology, which combines 3D tissue engineering, embedded neural electrodes, and AI-driven analysis, has demonstrated superior predictive performance compared to animal models, as evidenced by its retrospective Endurance Study. 28Bio operates primarily as a platform and services company, offering predictive assays to pharmaceutical partners to de-risk neurological drug development, and is currently in a pre-revenue stage.
Technology Platform
The Nexon™ platform integrates 3D tissue engineering (creating human brain & PNS organoids from iPSCs), neural interfacing (embedded electrodes for recording/stimulating activity), and artificial intelligence (to analyze neural data and predict clinical outcomes like seizure liability and neurotoxicity).
Opportunities
Risk Factors
Competitive Landscape
28Bio competes in the growing market for human-relevant preclinical models. Direct competitors include other biotech startups specializing in neural organoids or microelectrode array-based screening (e.g., Neurix, BrainXell, NETRI). It also faces competition from larger CROs incorporating organoid technologies and academic consortia. Its integrated AI-driven analysis and focus on clinical translation are key differentiators.